Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

Blood

Volumn 111, Issue 9, 2008, Pages 4477-4489

  Möricke, Anja ^b   Reiter, Alfred ^c   Zimmermann, Martin ^d   Gadner, Helmut ^e   Stanulla, Martin ^d   Dördelmann, Michael ^d   Löning, Lutz ^f   Beier, Rita ^g   Ludwig, Wolf Dieter ^h   Ratei, Richard ^h   Harbott, Jochen ^c   Boos, Joachim ⁱ   Mann, Georg ^e   Niggli, Felix ^j   Feldges, Andreas ^k   Henze, Günter ^l   Welte, Karl ^d   Beck, Jörn Dirk ^m   Klingebiel, Thomas ⁿ   Niemeyer, Charlotte ^o   Zintl, Felix ^p   Bode, Udo ^q   Urban, Christian ^r   Wehinger, Helmut ^s   Niethammer, Dietrich ^t   Riehm, Hansjörg ^d   Schrappe, Martin ^a,b   more..

^a German Austrian Swiss ALL BFM Study Group   (Switzerland)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f KLINIKUM OLDENBURG   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h Section of Pathology   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^k Ostschweizer Kinderspital   (Switzerland)

^l HUMBOLDT UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁿ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p JENA UNIVERSITY HOSPITAL   (Germany)

^q UNIVERSITY HOSPITAL BONN   (Germany)

^r MEDICAL UNIVERSITY OF GRAZ   (Austria)

^s KLINIKUM KASSEL   (Germany)

^t UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EVENT FREE SURVIVAL; FEMALE; GENETIC RISK; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INFANT; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SCHOOL CHILD; SKULL IRRADIATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LYMPHATIC LEUKEMIA; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; CYTARABINE; FEMALE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 47149100125     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-112920     Document Type: Article

References (74)

1. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990;33:439-450.
2. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
3. Schrappe M. Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205-2222.
4. Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies. 1982-1995. Leukemia. 2000;14:2196-2204.
5. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia. 2000;14:2234-2239.
6. Kamps WA, Veerman AJ, van Wering ER, van Weerden JF, Slater R, van der Does-van den Berg A. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia. 1984-1991. Leukemia. 2000;14:2240-2246.
7. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000:14:2247-2256.
8. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: aCLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14:2257-2266.
9. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000;14:2276-2285.
10. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
11. Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia. 2000;14:2295-2306.
12. Eden OB, Harrison G, Richards S, et al. Longterm follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997: Medical Research Council Childhood Leukaemia Working Party. Leukemia. 2000;14:2307-2320.
13. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000; 14:2267-2275.
14. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
15. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
16. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves eventfree survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
17. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia. 2002;16:1099-1111.
18. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
19. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;368:1339-1348.
20. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129:734-745.
21. Moghrabi A. Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007;109:896-904.
22. Riehm H, Reiter A, Schrappe M, et al. The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin Padiatr. 1987;199:151-160.
23. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-3133.
24. Conter V, Valsecchi MG, Silvestri D, et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet. 2007;369:123-131.
25. Schrauder A, Reiter A, Gadner H, et al. Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol. 2006;24:5742-5749.
26. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet. 2005;366:635-642.
27. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
28. Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood. 1998;92:1898-1909.
29. Hiddemann W, Wormann B, Ritter J, et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann N Y Acad Sci. 1986; 468:227-240.
30. Harbott J, Ritterbach J, Ludwig WD, Bartram CR, Reiter A, Lampert F. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. Recent Results Cancer Res. 1993;131:123-132.
31. Schlieben S, Borkhardt A. Reinisch I, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL): a prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia. 1996;10:957-963.
32. Viehmann S. Borkhardt A. Lampert F, Harbott J. Multiplex PGR: a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia. Ann Hematol. 1999;78:157-162.
33. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials: Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571-577.
34. Welte K. Reiter A. Mempel K, et al. A randomized phase-Ill study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: Berlin-Frankfurt-Munster Study Group. Blood. 1996;87:3143-3150.
35. Ahlke E. Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997:96:675-681.
36. Boos J, Werber G. Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996;32A:1544-1550.
37. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
38. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
39. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187.
40. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data (ed 1). New York: John Wiley and Sons; 1980:163-188.
41. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
42. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1:121-129.
43. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370:240-250.
44. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-550.
45. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer. 2003;97:1991-1998.
46. Kremer LC, van Dalen EC, Offringa M. Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191-196.
47. Prestor VV, Rakovec P, Kozelj M, Jereb B. Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood. Pediatr Hematol Oncol. 2000;17:527-540.
48. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-2636.
49. Messinger Y, Uckun FM. Acritical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. Leuk Lymphoma. 1999;34:415-432.
50. Chessells JM. Richards SM. Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol. 1995;89:364-372.
51. Shuster JJ, Wacker P, Pullen J, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2854-2863.
52. Pui CH, Boyett JM, Relling MV, etal. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999:17:818-824.
53. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet. 1996;347:1783-1788.
54. Effects of varying radiation schedule, cyclophosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia: Report to the Medical Research Council by the Working Party on Leukaemia in Childhood. Br Med J 1978;2:787-791.
55. Duration of chemotherapy in childhood acute lymphoblastic leukaemia: the Medical Research Council's Working Party on Leukaemia in Childhood. Med Pediatr Oncol. 1982;10:511-520.
56. Chessells JM, Durrant J, Hardy RM, Richards S. Medical Research Council leukaemia trial-UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood. J Clin Oncol. 1986;4:1758-1764.
57. Paolucci G, Masera G, Vecchi V, Marsoni S, Pession A, Zurlo MG. Treating childhood acute lymphoblastic leukaemia (ALL): summary of ten years' experience in Italy. ALL Steering Committee of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Med Pediatr Oncol. 1989;17:83-91.
58. Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII: Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood. Br J Haematol. 1991;78:187-196.
59. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol. 1998;16:3761-3767.
60. Löning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000:95:2770-2775.
61. Hata M, Oginol, Aida N.et al. Prophylactic cranial irradiation of acute lymphoblastic leukemia in childhood: outcomes of late effects on pituitary function and growth in long-term survivors. Int J Cancer. 2001;96(suppl):117- 124.
62. Langer T, Martus P, Ottensmeier H, Hertzberg H, Beck JD, Meier W. CNS late-effects after ALL therapy in childhood: III. Neuropsychologic performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol. 2002;38:320-328.
63. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293-310.
64. Spiegler BJ, Kennedy K, Maze R, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol. 2006;24:3858-3864.
65. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy. A Children's Cancer Group Report. J Clin Oncol. 1993:11:520-526.
66. Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol. 1998;16:920-930.
67. LeClerc JM. Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002:20:237-246.
68. Millot F, Suciu S, Philippe N, et al. Value of highdose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol. 2001;19:1935-1942.
69. Harris MB, Shuster JJ, Pullen DJ, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2840-2847.
70. Jackson RC, Harkrader RJ. Synergistic and antagonistic interactions of methotrexate and 1-beta-D-arabinofuranosylcytosine in hepatoma cells: the modulating effect of purines. Biochem Pharmacol. 1981;30:223-229.
71. Cadman E, Eiferman F. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest. 1979;64:788-797.
72. Akutsu M, Furukawa Y, Tsunoda S, Izumi T Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia. 2002;16:1808-1817.
73. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
74. Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420-426.